Skip to Content

Join the 'Sargramostim' group to help and get support from people like you.

Sargramostim News

Combo Treatment for Advanced Melanoma Seems to Improve Survival

Posted 4 Nov 2014 by

TUESDAY, Nov. 4, 2014 – Patients with advanced melanoma may live longer when treated with a combination of the cancer drug Yervoy and the immune system booster sargramostim, a new study finds. Patients given the two drugs had a median survival of 17.5 months, compared to 12.7 months for those on Yervoy (ipilimumab) alone. At one year, overall survival was nearly 69 percent for those on the ...

Ask a Question

Further Information

Related Condition Support Groups

Neutropenia Associated with Chemotherapy, Aplastic Anemia, Bone Marrow Transplantation, Bone Marrow Transplantation, Failure or Engraftment Delay, Bone Marrow Transplantation, Myeloid Reconstruction, Neutropenia Associated with Radiation

Related Drug Support Groups


Sargramostim Patient Information at